The Arora Report

Rss Facebook Twitter Linkedin

Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

HERE’S THE CASE FOR DOW 30,000 IN TRUMP’S FIRST TERM $AMAT $AMZN $BAC $ETFC $FB $GOOG $GOOGL $JPM $MU $RDSB $TMUS

February 17, 2017

The fundamental case for Dow 30,000 during Donald Trump’s first term has strengthened as earnings season winds down. Interestingly, this is happening at a time when, from a technical perspective, the stock market has staged a successful breakout of low volatility since the election. Still, there are two danger signs, as shown on the annotated chart. Please click here for the annotated chart. The biggest single factor in the long-term direction of stocks is earnings growth. The current consensus for S&P 500 Index SPX  operating earnings (often traded using the SPDR S&P 500 SPY ), are $133 per share. According to

Read More »

A NEW IDEA ON SNAPCHAT $SNAP $TWTR

February 16, 2017

This post was just published on ZYX Buy Change Alert. SNAP is an upcoming IPO of a company similar to TWTR.  Consider up to 60% of the full core position size in the IPO at the IPO price.  To be absolutely clear this is not a call to buy in the after market after the IPO starts trading. Consider stops in the zone of $0.03 to $0.13 below the IPO price. Please note that if you are an individual investor trading with online brokers, you are not likely to get this IPO.  You are receiving less than 2% of the content from

Read More »

STOCKS RUN UP ON ABENOMICS TRIUMPH OVER TRUMP BUT BAD SIGN FOR GOLD $SPY $GLD $SLV $GDX $GDXJ $NUGT $DUST $AAPL $BA $AVGO $NVDA $SWKS $EWY $KF

February 13, 2017

Donald Trump has accused countries including China and Japan of manipulating their currencies and running large trade deficits with the U.S. Investors in Asia were on edge leading into the meeting between Japanese Prime Minister Shinzo Abe and Trump late last week. The economic policies of Abe, known as Abenomics, rely in part on a weak Japanese yen and exports to the U.S. There is a clear conflict between Abenomics and Trump’s policies. The news was that the meeting between Abe and Trump ended with handshakes, hugs, golf and a statement by Trump that he supports Japan “100%.” But the

Read More »

WEEKLY MARKET DIGEST: NEW HIGHS IN STOCKS ON TRUMP PROMISE BUT STILL NOT ALL CLEAR WITHOUT A PULLBACK FIRST $GLD $QQQ $SLV $SPY $TBT $USO

February 10, 2017

   Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers of The Arora Report.  Please scroll down for the section What To Do Now. NEW HIGHS IN STOCKS ON TRUMP PROMISE BUT STILL NOT ALL CLEAR FOR ANOTHER LEG UP WITHOUT A PULLBACK FIRST, BLOW TO TRUMP, SMART MONEY

Read More »

MEAD JOHNSON BUYOUT TALKS CONTINUE $MJN $RBGLY $DANOY $NSRGY $KHC

February 7, 2017

This post was just published on ZYX Buy Change Alert. MJN is long from $66.26.  It is trading at $84.25 as of this writing. MJN continues buyout talks with RBGLY.  The offer is reportedly worth $90 per share.  Other potential suitors are DANOY, NSRGY, and KHC.  From our last post , Profits have been taken on all but 10% of the position in MJN.  Consider raising stops on the remaining in the zone of $69.23 to $69.38.  There is still a buyout potential and that is the reason to hold the remaining small quantity with a tight stop. The stock dipped into

Read More »

WEEKLY MARKET DIGEST: IMPORTANT INDICATOR OF THE FUTURE SHIFTS ON JOBS REPORT $DIA $GLD $QQQ $SLV $SPY $TBF $TBT $USO

February 3, 2017

   Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers of The Arora Report.  Please scroll down for the section What To Do Now. IMPORTANT INDICATOR OF THE FUTURE SHIFTS ON JOBS REPORT February 3, 2017 This is what you need to know today. Over my 35 years in

Read More »

UPGRADING INDIA ON POSITIVE BUDGET $EPI

February 2, 2017

    This post was just published on ZYX Global Multi Asset Allocation Alert.   Unlike the United States, annual budget in India of the central government (equivalent of the federal government in the United States) is one of the most important events that influences the Indian stock market.   The budget just presented was mostly as expected.  It lays out the ground work for producing a strong macro economic environment and also to implement further reforms.  There was fear, especially among foreign investors in the Indian market that the budget would increase long-term capital gains tax.  This speculation was due to a statement

Read More »

MOMENTA PHARMACEUTICALS JUMPS ON COPAXONE RULING, TAKE PROFITS AND EXIT THE POSITION IF STILL HOLDING $MNTA $MYL $TEVA

February 2, 2017

This post was published on ZYX Buy Change Alert. MNTA has an average price of $11.31.  As of this writing it is trading at $19.05. The stock has jumped on a court invalidating TEVA patent on a MS drug Copaxone.  This was part of the original thesis to buy MNTA.  MYL is the other beneficiary. The stock previously hit the target zone but not the upper band of the target zone until yesterday.  It appears that many subscribers are still holding. Consider taking profits on the position, if still holding, in the zone of $18.43 to $20.88 and exit the position.  As

Read More »

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content